ReST Therapeutics

Executive Summary

ReST Therapeutics is a French clinical-stage biotechnology company (founded 2020) developing transformative small molecule therapies for neuropsychiatric disorders, primarily Post-Traumatic Stress Disorder (PTSD) and Alzheimer's Disease. The company employs a precision medicine approach to target stress and trauma-related pathways, aiming to help patients reclaim their lives. As a private, pre-clinical company with no disclosed funding, ReST faces significant hurdles typical of early-stage biotech: validating its therapeutic candidates through rigorous preclinical studies, securing financing for IND-enabling work, and eventually moving into human trials. The company’s focus on PTSD and Alzheimer’s addresses large unmet medical needs, but the lack of public data or partnership announcements limits visibility. If successful, ReST could offer differentiated oral therapies for conditions with limited treatment options. However, the pre-clinical stage, absence of disclosed funding, and competitive landscape for Alzheimer’s treatments (including anti-amyloid antibodies) warrant caution. The company’s science and team are untested publicly, making its trajectory uncertain.

Upcoming Catalysts (preview)

• Q4 2026Preclinical proof-of-concept data for lead program20% success
• Q2 2027Series A funding round or grant announcement35% success
• TBDStrategic partnership or licensing deal for Alzheimer's candidate10% success